A novel somatic mutation in GNB2 provides new insights to the pathogenesis of Sturge-Weber syndrome.


Journal

Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958

Informations de publication

Date de publication:
13 10 2021
Historique:
received: 13 01 2021
revised: 25 05 2021
accepted: 25 05 2021
pubmed: 15 6 2021
medline: 1 4 2022
entrez: 14 6 2021
Statut: ppublish

Résumé

Sturge-Weber syndrome (SWS) is a neurocutaneous disorder characterized by vascular malformations affecting skin, eyes and leptomeninges of the brain, which can lead to glaucoma, seizures and intellectual disability. The discovery of a disease-causing somatic missense mutation in the GNAQ gene, encoding an alpha chain of heterotrimeric G-proteins, has initiated efforts to understand how G-proteins contribute to SWS pathogenesis. The mutation is predominantly detected in endothelial cells and is currently believed to affect downstream MAPK signalling. In this study of six Norwegian patients with classical SWS, we aimed to identify somatic mutations through deep sequencing of DNA from skin biopsies. Surprisingly, one patient was negative for the GNAQ mutation, but instead harbored a somatic mutation in GNB2 (NM_005273.3:c.232A>G, p.Lys78Glu), which encodes a beta chain of the same G-protein complex. The positions of the mutant amino acids in the G-protein are essential for complex reassembly. Therefore, failure of reassembly and continuous signalling is a likely consequence of both mutations. Ectopic expression of mutant proteins in endothelial cells revealed that expression of either mutant reduced cellular proliferation, yet regulated MAPK signalling differently, suggesting that dysregulated MAPK signalling cannot fully explain the SWS phenotype. Instead, both mutants reduced synthesis of Yes-associated protein (YAP), a transcriptional co-activator of the Hippo signalling pathway, suggesting a key role for this pathway in the vascular pathogenesis of SWS. The discovery of the GNB2 mutation sheds novel light on the pathogenesis of SWS and suggests that future research on targets of treatment should be directed towards the YAP, rather than the MAPK, signalling pathway.

Identifiants

pubmed: 34124757
pii: 6297427
doi: 10.1093/hmg/ddab144
pmc: PMC8522634
doi:

Substances chimiques

GNB2 protein, human 0
Protein Subunits 0
Nortriptyline BL03SY4LXB
GTP-Binding Proteins EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1919-1931

Subventions

Organisme : NIMH NIH HHS
ID : U01 MH106884
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press.

Références

Cells. 2019 May 01;8(5):
pubmed: 31052445
J Child Neurol. 2003 Aug;18(8):509-16
pubmed: 13677575
Nutrients. 2014 Apr 21;6(4):1618-34
pubmed: 24763109
Nat Med. 2015 Jan;21(1):71-5
pubmed: 25485910
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
J Invest Dermatol. 2020 May;140(5):1110-1113
pubmed: 31838126
In Vitro Cell Dev Biol Anim. 1995 Jun;31(6):447-55
pubmed: 8589888
JAMA Dermatol. 2014 Dec;150(12):1336-40
pubmed: 25188413
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Oncogene. 2017 Jan 26;36(4):534-545
pubmed: 27321186
Nature. 1996 Jan 25;379(6563):311-9
pubmed: 8552184
J Cell Sci. 2014 Feb 15;127(Pt 4):709-17
pubmed: 24532814
J Neuropathol Exp Neurol. 2007 Jan;66(1):86-97
pubmed: 17204940
J Hum Genet. 2014 Dec;59(12):691-3
pubmed: 25374402
Nat Protoc. 2006;1(2):586-603
pubmed: 17406286
J Invest Dermatol. 2021 Mar;141(3):685-688
pubmed: 32771470
N Engl J Med. 2013 May 23;368(21):1971-9
pubmed: 23656586
Cancer Cell. 2014 Jun 16;25(6):822-30
pubmed: 24882516
Neurol Genet. 2018 May 01;4(3):e236
pubmed: 29725622
Cell. 2012 Aug 17;150(4):780-91
pubmed: 22863277
J Am Acad Dermatol. 1987 Apr;16(4):899-906
pubmed: 3033033
PLoS One. 2015 Jul 20;10(7):e0133158
pubmed: 26192947
Nature. 2009 Jan 29;457(7229):599-602
pubmed: 19078957
Cancer Cell. 2014 Jun 16;25(6):831-45
pubmed: 24882515
Plast Reconstr Surg. 2016 Jan;137(1):77e-82e
pubmed: 26368330
Pediatr Neurol. 2017 Feb;67:59-63
pubmed: 27919468
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Nat Rev Mol Cell Biol. 2008 Jan;9(1):60-71
pubmed: 18043707
J Clin Invest. 1973 Nov;52(11):2745-56
pubmed: 4355998
Neuropediatrics. 2017 Oct;48(5):385-389
pubmed: 28571101
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Front Cell Dev Biol. 2019 Apr 10;7:49
pubmed: 31024911
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Development. 2014 Apr;141(8):1614-26
pubmed: 24715453
Pediatr Neurol. 2016 May;58:12-24
pubmed: 27268758
Bioinformatics. 2016 May 15;32(10):1592-4
pubmed: 26819469

Auteurs

Roar Fjær (R)

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo 0424, Norway.
Department of Neurology and Clinical Neurophysiology, St. Olavs University Hospital, Trondheim 3250, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo 0424, Norway.

Katarzyna Marciniak (K)

K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo 0424, Norway.
Department of Pathology, Oslo University Hospital, Oslo 0424, Norway.

Olav Sundnes (O)

K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo 0424, Norway.
Department of Pathology, Oslo University Hospital, Oslo 0424, Norway.
Department of Dermatology, Oslo University Hospital, Oslo 0424, Norway.

Hanne Hjorthaug (H)

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo 0424, Norway.

Ying Sheng (Y)

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo 0424, Norway.

Clara Hammarström (C)

K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo 0424, Norway.
Department of Pathology, Oslo University Hospital, Oslo 0424, Norway.

Jan Cezary Sitek (JC)

Department of Dermatology, Oslo University Hospital, Oslo 0424, Norway.

Magnus Dehli Vigeland (MD)

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo 0424, Norway.

Paul Hoff Backe (PH)

Institute of Clinical Medicine, University of Oslo, Oslo 0424, Norway.
Department of Microbiology, Oslo University Hospital, Oslo 0424, Norway.
Department of Medical Biochemistry, Oslo University Hospital, Oslo 0424, Norway.

Ane-Marte Øye (AM)

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo 0424, Norway.

Johanna Hol Fosse (JH)

K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo 0424, Norway.
Department of Pathology, Oslo University Hospital, Oslo 0424, Norway.

Tor Espen Stav-Noraas (TE)

K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo 0424, Norway.

Yuri Uchiyama (Y)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
Department of Rare Disease Genomics, Yokohama City University Hospital, Yokohama 236-0004, Japan.

Naomichi Matsumoto (N)

Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.

Anne Comi (A)

Department of Neurology, Hugo Moser Kennedy Krieger Research Institute, Baltimore, MD 21205, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Jonathan Pevsner (J)

Department of Neurology, Hugo Moser Kennedy Krieger Research Institute, Baltimore, MD 21205, USA.
Department of Psychiatry and Behavioral Sciences, John Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Guttorm Haraldsen (G)

K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo 0424, Norway.
Department of Pathology, Oslo University Hospital, Oslo 0424, Norway.

Kaja Kristine Selmer (KK)

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo 0424, Norway.
National Centre for Rare Epilepsy-related Disorders, Oslo University Hospital and the University of Oslo, Oslo 0424, Norway.
Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo 0424, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH